Burnet, F. M. Immunological aspects of malignant disease. Lancet 1967, 289, 1171–1174.
Oiseth, S. J.; Aziz, M. S. Cancer immunotherapy: a brief review of the history, possibilities,
and challenges ahead. Journal of Cancer Metastasis and Treatment 2017, 3, 250–261.
Waldman, A.D.; Fritz, J. M.; Lenardo, M. J. A guide to cancer immunotherapy: from T cell
basic science to clinical practice. Nature Reviews Immunology 2020, 20, 651–668.
Kubli, S. P.; Berger, T.; Araujo, D. V.; Siu, L. L.; Mak, T. W. Beyond immune checkpoint
blockade: emerging immunological strategies. Nature Reviews Drug Discovery 2021, 20, 899–
919.
Alsaab, H. O.; Sau, S.; Alzhrani, R.; Tatiparti, K.; Bhise, K.; Kashaw, S. K.; Iyer, A. K. PD-1
and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: Mechanism,
combinations, and clinical outcome. Frontiers in Pharmacology 2017, 8, 561.
Mellman, I.; Coukos, G.; Dranoff, G. Cancer immunotherapy comes of age. Nature 2011, 480,
480–489.
Fésüs, V. Recent advances of immunooncology in the treatment of solid tumours and
haematological malignancies: the immune checkpoint inhibitors. Magyar Onkologia 2017, 61,
116–125.
https://www.cancerresearch.org/en-us/immunotherapy/timeline-of-progress
Nirschl, C. J.; Drake, C. G. Molecular pathways: coexpression of immune checkpoint
molecules: signaling pathways and implications for cancer immunotherapy. Clinical Cancer
Research 2013, 19, 4917–4924.
10
OʼDay, S. J.; Hamid, O.; Urba, W. J. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a
novel strategy for the treatment of melanoma and other malignancies. Cancer 2007, 110, 2614‒
2627.
145
11
Poust J. Targeting metastatic melanoma. American Journal of Health-System Pharmacy 2008,
65(24 Suppl 9), S9–S15.
12
Waterhouse, P.; Penninger, J. M.; Timms, E.; Wakeham, A.; Shahinian, A.; Lee, K. P.;
Thompson, C. B.; Griesser, H.; Mak, T. W. Lymphoproliferative disorders with early lethality
in mice deficient in Ctla-4. Science 1995, 270, 985–988.
13
Grosso, J. F.; Jure-Kunkel, M. N. CTLA-4 blockade in tumor models: an overview of
preclinical and translational research. Cancer Immunity 2013, 13, 5.
14
Liu, X.; Guo, C. Y.; Tou, F. F.; Wen, X. M.; Kuang, Y. K.; Zhu, Q.; Hu, H. Association of PDL1 expression status with the efficacy of PD-1/PD-L1 inhibitors and overall survival in solid
tumours: A systematic review and meta-analysis. International Journal of Cancer 2020, 147,
116–127.
15
Hodi, F. S.; O'Day, S. J.; McDermott, D. F.; Weber, R. W.; Sosman, J. A.; Haanen, J. B.;
Gonzalez, R.; Robert, C.; Schadendorf, D.; Hassel, J. C.; Akerley, W.; van den Eertwegh, A.
J.; Lutzky, J.; Lorigan, P.; Vaubel, J. M.; Linette, G. P.; Hogg, D.; Ottensmeier, C. H.; Lebbé,
C.; Peschel, C.; Quirt, I.; Clark, J. I.; Wolchok, J. D.; Weber, J. S.; Tian, J.; Yellin, M. J.; Nichol,
G. M.; Hoos, A.; Urba, W. J. Improved survival with ipilimumab in patients with metastatic
melanoma. New England Journal of Medicine 2010, 363, 711–723.
16
Ishida, Y.; Agata, Y.; Shibahara, K.; Honjo, T. Induced expression of PD-1, a novel member of
the immunoglobulin gene superfamily, upon programmed cell death. EMBO Journal 1992, 11,
3887–3895.
17
Chemnitz, J. M.; Parry, R. V.; Nichols, K. E.; June, C. H.; Riley, J. L. SHP-1 and SHP-2
associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon
primary human T cell stimulation, but only receptor ligation prevents T cell activation. Journal
of Immunology 2004, 173, 945–954.
146
18
Nishimura, H.; Okazaki, T.; Tanaka, Y.; Nakatani, K.; Hara, M.; Matsumori, A.; Sasayama, S.;
Mizoguchi, A.; Hiai, H.; Minato, N.; Honjo, T. Autoimmune dilated cardiomyopathy in PD-1
receptor-deficient mice. Science 2001, 291, 319–322.
19
Nishimura, H.; Nose, M.; Hiai, H.; Minato, N.; Honjo, T. Development of lupus-like
autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying
immunoreceptor. Immunity 1999, 11, 141–151.
20
Okazaki, T.; Honjo, T. PD-1 and PD-1 ligands: from discovery to clinical application.
International Immunology 2007, 19, 813–824.
21
Freeman, G. J.; Long, A. J.; Iwai, Y.; Bourque, K.; Chernova, T.; Nishimura, H.; Fitz, L. J.;
Malenkovich, N.; Okazaki, T.; Byrne, M. C.; Horton, H. F.; Fouser, L.; Carter, L.; Ling, V.;
Bowman, M. R.; Carreno, B. M.; Collins, M.; Wood, C. R.; Honjo, T. Engagement of the PD1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of
lymphocyte activation. Journal of Experimental Medicine, 2000, 192, 1027–1034.
22
Keir, M. E.; Butte, M. J.; Freeman, G. J.; Sharpe, A. H. PD-1 and its ligands in tolerance and
immunity. Annual Review of Immunology 2008, 26, 677–704.
23
Keir, M. E.; Liang, S. C.; Guleria, I.; Latchman, Y. E.; Qipo, A.; Albacker, L. A.; Koulmanda,
M.; Freeman, G. J.; Sayegh, M. H.; Sharpe, A. H. Tissue expression of PD-L1 mediates
peripheral T cell tolerance. Journal of Experimental Medicine 2006, 203, 883–895.
24
Dong, H.; Strome, S. E.; Salomao, D. R.; Tamura, H.; Hirano, F.; Flies, D. B.; Roche, P. C.;
Lu, J.; Zhu, G.; Tamada, K.; Lennon, V. A.; Celis, E.; Chen, L. Tumor-associated B7-H1
promotes T-cell apoptosis: a potential mechanism of immune evasion. Nature Medicine 2002,
8, 793–800.
25
Blank, C.; Brown, I.; Peterson, A. C.; Spiotto, M.; Iwai, Y.; Honjo, T.; Gajewski, T. F. PDL1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic
147
CD8+ T cells. Cancer Research, 2004, 64, 1140–1145.
26
Okazaki, T.; Honjo, T. The PD-1-PD-L pathway in immunological tolerance. Trends in
Immunology 2006, 27, 195–201.
27
Dong, H.; Zhu, G.; Tamada, K.; Chen, L. B7-H1, a third member of the B7 family, costimulates T-cell proliferation and interleukin-10 secretion. Nature Medicine 1999, 5, 1365–
1369.
28
Freeman, G. J.; Long, A. J.; Iwai, Y.; Bourque, K.; Chernova, T.; Nishimura, H.; Fitz, L. J.;
Malenkovich, N.; Okazaki, T.; Byrne, M. C.; Horton, H. F.; Fouser, L.; Carter, L.; Ling, V.;
Bowman, M. R.; Carreno, B. M.; Collins, M.; Wood, C. R.; Honjo, T. Engagement of the PD1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of
lymphocyte activation. Journal of Experimental Medicine 2000, 192, 1027–1034.
29
Tamura, H.; Ishibashi, M.; Yamashita, T.; Tanosaki, S.; Okuyama, N.; Kondo, A.; Hyodo, H.;
Shinya, E.; Takahashi, H.; Dong, H.; Tamada, K.; Chen, L.; Dan, K.; Ogata, K. Marrow stromal
cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in
multiple myeloma. Leukemia 2013, 27, 464–472.
30
Kondo, A.; Yamashita, T.; Tamura, H.; Zhao, W.; Tsuji, T.; Shimizu, M.; Shinya, E.; Takahashi,
H.; Tamada, K.; Chen, L.; Dan, K.; Ogata, K. Interferon-gamma and tumor necrosis factoralpha induce an immunoinhibitory molecule, B7-H1, via nuclear factor-kappaB activation in
blasts in myelodysplastic syndromes. Blood 2010, 116, 1124–1131.
31
Yamamoto, R.; Nishikori, M.; Kitawaki, T.; Sakai, T.; Hishizawa, M.; Tashima, M.; Kondo, T.;
Ohmori, K.; Kurata, M.; Hayashi, T.; Uchiyama, T. PD-1-PD-1 ligand interaction contributes
to immunosuppressive microenvironment of Hodgkin lymphoma. Blood 2008, 111, 3220–
3224.
32
Latchman, Y.; Wood, C. R.; Chernova, T.; Chaudhary, D.; Borde, M.; Chernova, I.; Iwai, Y.;
148
Long, A. J.; Brown, J. A.; Nunes, R.; Greenfield, E. A.; Bourque, K.; Boussiotis, V. A.; Carter,
L. L.; Carreno, B. M.; Malenkovich, N.; Nishimura, H.; Okazaki, T.; Honjo, T.; Sharpe, A. H.;
Freeman, G. J. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nature
Immunology 2001, 2, 261–268.
33
Francisco, L. M.; Sage, P. T.; Sharpe, A. H. The PD-1 pathway in tolerance and
autoimmunity. Immunological Reviews 2010, 236, 219–242.
34
Freeman, G. J.; Long, A. J.; Iwai, Y.; Bourque, K.; Chernova, T.; Nishimura, H.; Fitz, L. J.;
Malenkovich, N.; Okazaki, T.; Byrne, M. C.; Horton, H. F.; Fouser, L.; Carter, L.; Ling, V.;
Bowman, M. R.; Carreno, B. M.; Collins, M.; Wood, C. R.; Honjo, T. Engagement of the PD1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of
lymphocyte activation. Journal of Experimental Medicine 2000, 192, 1027–1034.
35
Seliger B. Basis of PD1/PD-L1 Therapies. Journal of Clinical Medicine, 2019, 8, 2168.
36
Akinleye, A.;
Rasool, Z.
Immune checkpoint inhibitors of
PD-L1 as
cancer
therapeutics. Journal of Hematology & Oncology 2019, 12, 92.
37
Viteri, S.; González-Cao, M.; Barrón, F.; Riso, A.; Rosell, R. Results of clinical trials with antiprogrammed death 1/programmed death ligand 1 inhibitors in lung cancer. Translational Lung
Cancer Research 2015, 4, 756–762.
38
Vaddepally, R. K.; Kharel, P.; Pandey, R.; Garje, R.; Chandra, A. B. Review of indications of
FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence.
Cancers 2020, 12, 738.
39
Lee, H. T.; Lee, S. H.; Heo, Y. S. Molecular interactions of antibody drugs targeting PD-1, PDL1, and CTLA-4 in immuno-oncology. Molecules 2019, 24, 1190.
40
https://www.cancerresearch.org/en-us/scientists/immuno-oncology-landscape/fda-approvaltimeline-of-active-immunotherapies
149
41
Sasikumar, P. G.; Ramachandra, M. Small-molecule antagonists of the immune checkpoint
pathways: concept to clinic. Future Medicinal Chemistry 2017, 9, 1305–1308.
42
Mondanelli, G.; Volpi, C.; Orabona, C.; Grohmann, U. Challenges in the design of reliable
immuno-oncology mouse models to inform drug development. Future Medicinal Chemistry
2017, 9, 1313–1317.
43
Chen, T.; Li, Q.; Liu, Z.; Chen, Y.; Feng, F.; Sun, H. Peptide-based and small synthetic
molecule inhibitors on PD-1/PD-L1 pathway: A new choice for immunotherapy? European
Journal of Medicinal Chemistry 2019, 161, 378–398.
44
Pardoll D. M. The blockade of immune checkpoints in cancer immunotherapy. Nature Reviews
Cancer 2012, 12, 252–264.
45
Ghosh, A.; Barba, P.; Perales, M. A. Checkpoint inhibitors in AML: are we there yet?. British
Journal of Haematology 2020, 188, 159–167.
46
Redelman-Sidi, G.; Michielin, O.; Cervera, C.; Ribi, C.; Aguado, J. M.; Fernández-Ruiz, M.;
Manuel, O. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus
Document on the safety of targeted and biological therapies: an infectious diseases perspective
(Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor
modulators and proteasome inhibitors). Clinical Microbiology and Infection 2018, 24(Suppl
2), S95–S107.
47
Brahmer, J. R.; Tykodi, S. S.; Chow, L. Q.; Hwu, W. J.; Topalian, S. L.; Hwu, P.; Drake, C. G.;
Camacho, L. H.; Kauh, J.; Odunsi, K.; Pitot, H. C.; Hamid, O.; Bhatia, S.; Martins, R.; Eaton,
K.; Chen, S.; Salay, T. M.; Alaparthy, S.; Grosso, J. F.; Korman, A. J.; Parker, S. M.; Agrawal,
S.; Goldberg, S. M.; Pardoll, D. M.; Gupta, A.; Wigginton, J. M. Safety and activity of antiPD-L1 antibody in patients with advanced cancer. New England Journal of Medicine 2012,
366, 2455–2465.
150
48
Brahmer, J. R.; Drake, C. G.; Wollner, I.; Powderly, J. D.; Picus, J.; Sharfman, W. H.;
Stankevich, E.; Pons, A.; Salay, T. M.; McMiller, T. L.; Gilson, M. M.; Wang, C.; Selby, M.;
Taube, J. M.; Anders, R.; Chen, L.; Korman, A. J.; Pardoll, D. M.; Lowy, I.; Topalian, S. L.
Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid
tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. Journal of
Clinical Oncology 2010, 28, 3167–3175.
49
Topalian, S. L.; Hodi, F. S.; Brahmer, J. R.; Gettinger, S. N.; Smith, D. C.; McDermott, D. F.;
Powderly, J. D.; Carvajal, R. D.; Sosman, J. A.; Atkins, M. B.; Leming, P. D.; Spigel, D. R.;
Antonia, S. J.; Horn, L.; Drake, C. G.; Pardoll, D. M.; Chen, L.; Sharfman, W. H.; Anders, R.
A.; Taube, J. M.; McMiller, T.L.; Xu, H.; Korman, A. J.; Jure-Kunkel, M.; Agrawal, S.;
McDonald, D.; Kollia, G. D.; Gupta, A.; Wigginton, J. M.; Sznol, M. Safety, activity, and
immune correlates of anti-PD-1 antibody in cancer. New England Journal of Medicine 2012,
366, 2443–2454.
50
Akbari, O.; Stock, P.; Singh, A. K.; Lombardi, V.; Lee, W. L.; Freeman, G. J.; Sharpe, A. H.;
Umetsu, D. T.; Dekruyff, R. H. PD-L1 and PD-L2 modulate airway inflammation and iNKTcell-dependent airway hyperreactivity in opposing directions. Mucosal Immunology 2010, 3,
81–91.
51
Maute, R. L.; Gordon, S. R.; Mayer, A. T.; McCracken, M. N.; Natarajan, A.; Ring, N. G.;
Kimura, R.; Tsai, J. M.; Manglik, A.; Kruse, A. C.; Gambhir, S. S.; Weissman, I. L.; Ring, A.
M. Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET
imaging. Proceedings of the National Academy of Sciences of the United States of
America 2015, 112, E6506–E6514.
52
Andrews A. Treating with checkpoint inhibitors-figure $1 million per patient. American Health
& Drug Benefits 2015, 8(Spec Issue), 9.
151
53
Yang, J.; Hu, L. Immunomodulators targeting the PD-1/PD-L1 protein-protein interaction:
From antibodies to small molecules. Medicinal Research Reviews 2019, 39, 265–301.
54
Wang, T.; Wu, X.; Guo, C.; Zhang, K.; Xu, J.; Li, Z.; Jiang, S. Development of inhibitors of
the programmed cell death-1/programmed cell death-ligand 1 signaling pathway. Journal of
Medicinal Chemistry 2019, 62, 1715–1730.
55
Zhan, M. M.; Hu, X. Q.; Liu, X. X.; Ruan, B. F.; Xu, J.; Liao, C. From monoclonal antibodies
to small molecules: the development of inhibitors targeting the PD-1/PD-L1 pathway. Drug
Discovery Today 2016, 21, 1027–1036.
56
Konstantinidou, M.; Zarganes-Tzitzikas, T.; Magiera-Mularz, K.; Holak, T. A.; Dömling, A.
Immune Checkpoint PD-1/PD-L1: Is there life beyond antibodies?. Angewandte Chemie
(International ed. in English) 2018, 57, 4840–4848.
57
Zak, K. M.; Kitel, R.; Przetocka, S.; Golik, P.; Guzik, K.; Musielak, B.; Dömling, A.; Dubin,
G.; Holak, T. A. Structure of the complex of human programmed death 1, PD-1, and its ligand
PD-L1. Structure 2015, 23, 2341–2348.
58
Smith, M. C.; Gestwicki, J. E. Features of protein-protein interactions that translate into potent
inhibitors: topology, surface area and affinity. Expert Reviews in Molecular Medicine 2012, 14,
e16.
59
Ivanov, A. A.; Khuri, F. R.; Fu, H. Targeting protein-protein interactions as an anticancer
strategy. Trends in Pharmacological Sciences 2013, 34, 393–400.
60
Zhong, Y.; Li, X.; Yao, H.; Lin, K. The characteristics of PD-L1 inhibitors, from peptides to
small molecules. Molecules 2019, 24, 1940.
61
Guzik, K.; Tomala, M.; Muszak, D.; Konieczny, M.; Hec, A.; Błaszkiewicz, U.; Pustuła, M.;
Butera, R.; Dömling, A.; Holak, T. A. Development of the inhibitors that target the PD-1/PDL1
interaction-a
brief
look
at
progress
152
on
small
molecules,
peptides
and
macrocycles. Molecules 2019, 24, 2071.
62
Magiera-Mularz, K.; Skalniak, L.; Zak, K. M.; Musielak, B.; Rudzinska-Szostak, E.; Berlicki,
Ł.; Kocik, J.; Grudnik, P.; Sala, D.; Zarganes-Tzitzikas, T.; Shaabani, S.; Dömling, A.; Dubin,
G.; Holak, T. A. Bioactive macrocyclic inhibitors of the PD-1/PD-L1 immune
checkpoint. Angewandte Chemie (International ed. in English) 2017, 56, 13732–13735.
63
Sasikumar, P. G. N.; Ramachandra, M.; Naremaddepalli, S. S. S. 1,3,4-Oxadiazole and 1,3,4thiadiazole derivatives as immunomodulators. Patent: WO2015/033301, 2015.
64
Lee, J. J.; Powderly, J. D.; Patel, M. R.; Brody, J.; Hamilton, E. P.; Infante, J. R.; Gerald Steven
Falchook, G. S.; Wang, H.; Adams, L.; Gong, L.; Ma, A. W.; Wyant, T.; Lazorchak, A.;
Agarwal, S.; Tuck, D. P.; Daud, A. Phase 1 trial of CA-170, a novel oral small molecule dual
inhibitor of immune checkpoints PD-1 and VISTA, in patients (pts) with advanced solid tumor
or lymphomas. Journal of Clinical Oncology 2017, 35(15_suppl), TPS3099–TPS3099.
65
Musielak, B.; Kocik, J.; Skalniak, L.; Magiera-Mularz, K.; Sala, D.; Czub, M.; Stec, M.;
Siedlar, M.; Holak, T. A.; Plewka, J. CA-170 - A potent small-molecule PD-L1 inhibitor or
not? Molecules 2019, 24, 2804.
66
Chupak, L. S.; Zheng, X. Compounds useful as immunomodulators. Patent: WO2015/034820,
2015.
67
Louis S. Chupak.; Ding, M.; Martin, S. W.; Zheng, X.; Hewawasam, P.; Connolly, T. P.; Xu,
N.; Yeung, K.; Zhu, J.; Langley, D. R.; Tenney, D. J.; Scola, P. M. Compounds useful as
immunomodulators. Patent: WO2015/160641, 2015.
68
Zak, K. M.; Grudnik, P.; Guzik, K.; Zieba, B. J.; Musielak, B.; Dömling, A.; Dubin, G.; Holak,
T. A. Structural basis for small molecule targeting of the programmed death ligand 1 (PDL1). Oncotarget 2016, 7, 30323–30335.
69
Andrei, S. A.; Sijbesma, E.; Hann, M.; Davis, J.; O'Mahony, G.; Perry, M. W. D.; Karawajczyk,
153
A.; Eickhoff, J.; Brunsveld, L.; Doveston, R. G.; Milroy, L. G.; Ottmann, C. Stabilization of
protein-protein interactions in drug discovery. Expert Opinion on Drug Discovery 2017, 12,
925–940.
70
Petta, I.; Lievens, S.; Libert, C.; Tavernier, J.; De Bosscher, K. Modulation of protein-protein
interactions for the development of novel therapeutics. Molecular Therapy 2016, 24, 707–718.
71
Zarzycka, B.; Kuenemann, M. A.; Miteva, M. A.; Nicolaes, G. A. F.; Vriend, G.; Sperandio, O.
Stabilization of protein-protein interaction complexes through small molecules. Drug
Discovery Today 2016, 21, 48–57.
72
Waring, M. J.; Chen, H.; Rabow, A. A.; Walker, G.; Bobby, R.; Boiko, S.; Bradbury, R. H.;
Callis, R.; Clark, E.; Dale, I.; Daniels, D. L.; Dulak, A.; Flavell, L.; Holdgate, G.; Jowitt, T. A.;
Kikhney, A.; McAlister, M.; Méndez, J.; Ogg, D.; Patel, J.; Petteruti, P.; Robb, G. R.; Robers,
M. B.; Saif, S.; Stratton, N.; Svergun, D. I.; Wang, W.; Whittaker, D.; Wilson, D. M.; Yao, Y.
Potent and selective bivalent inhibitors of BET bromodomains. Nature Chemical Biology 2016,
12, 1097–1104.
73
Kaae, B. H.; Harpsøe, K.; Kastrup, J. S.; Sanz, A. C.; Pickering, D. S.; Metzler, B.; Clausen,
R. P.; Gajhede, M.; Sauerberg, P.; Liljefors, T.; Madsen, U. Structural proof of a dimeric
positive modulator bridging two identical AMPA receptor-binding sites. Chemistry &
Biology 2007, 14, 1294–1303.
74
Morin, M. D.; Wang, Y.; Jones, B. T.; Mifune, Y.; Su, L.; Shi, H.; Moresco, E. M. Y.; Zhang,
H.; Beutler, B.; Boger, D. L. Diprovocims: A new and exceptionally potent class of Toll-like
receptor agonists. Journal of the American Chemical Society 2018, 140, 14440–14454.
75
Wells, J. A.; McClendon, C. L. Reaching for high-hanging fruit in drug discovery at proteinprotein interfaces. Nature 2007, 450, 1001–1009.
76
Scott, D. E.; Bayly, A. R.; Abell, C.; Skidmore, J. Small molecules, big targets: drug discovery
154
faces the protein-protein interaction challenge. Nature Reviews Drug Discovery 2016, 15,
533–550.
77
RCSB Protein Data Bank (RCSB PDB). https://www.rcsb.org/
78
Lin, D. Y.; Tanaka, Y.; Iwasaki, M.; Gittis, A. G.; Su, H. P.; Mikami, B.; Okazaki, T.; Honjo,
T.; Minato, N.; Garboczi, D. N. The PD-1/PD-L1 complex resembles the antigen-binding Fv
domains of antibodies and T cell receptors. Proceedings of the National Academy of Sciences
of the United States of America 2008, 105, 3011–3016.
79
Chen, Y.; Liu, P.; Gao, F.; Cheng, H.; Qi, J.; Gao, G. F. A dimeric structure of PD-L1: functional
units or evolutionary relics? Protein & Cell 2010, 1, 153–160.
80
Guzik, K.; Zak, K. M.; Grudnik, P.; Magiera, K.; Musielak, B.; Törner, R.; Skalniak, L.;
Dömling, A.; Dubin, G.; Holak, T. A. Small-molecule inhibitors of the programmed cell death1/programmed death-ligand 1 (PD-1/PD-L1) interaction via transiently induced protein states
and dimerization of PD-L1. Journal of Medicinal Chemistry 2017, 60, 5857–5867.
81
Nguyen, H. H.; Park, J.; Kang, S.; Kim, M. Surface plasmon resonance: a versatile technique
for biosensor applications. Sensors 2015, 15, 10481–10510.
82
Han, Y.; Gao, Y.; He, T.; Wang, D.; Guo, N.; Zhang, X.; Chen, S.; Wang, H. PD-1/PD-L1
inhibitor screening of caffeoylquinic acid compounds using surface plasmon resonance
spectroscopy. Analytical Biochemistry 2018, 547, 52–56.
83
https://www.promega.jp/Products/Biologics/Functional-Bioassays/PD1_PDL1-BlockadeBioassays/?fq=blockade%20bioassay&catNum=J1250
84
https://www.promega.jp/products/reporter-bioassays/immune-checkpointbioassays/pd1_pdl1-blockade-bioassays/?catNum=J1250
85
Wang, C.; Thudium, K. B.; Han, M.; Wang, X. T.; Huang, H.; Feingersh, D.; Garcia, C.; Wu,
Y.; Kuhne, M.; Srinivasan, M.; Singh, S.; Wong, S.; Garner, N.; Leblanc, H.; Bunch, R. T.;
155
Blanset, D.; Selby, M. J.; Korman, A. J. In vitro characterization of the anti-PD-1 antibody
nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunology
Research 2014, 2, 846–856.
86
Basu, S.; Yang, J.; Xu, B.; Magiera-Mularz, K.; Skalniak, L.; Musielak, B.; Kholodovych, V.;
Holak, T. A.; Hu, L. Design, synthesis, evaluation, and structural studies of C2-symmetric small
molecule inhibitors of programmed cell death-1/programmed death-ligand 1 protein-protein
interaction. Journal of Medicinal Chemistry 2019, 62, 7250–7263.
87
Copeland R. A. The dynamics of drug-target interactions: drug-target residence time and its
impact on efficacy and safety. Expert Opinion on Drug Discovery 2010, 5, 305–310.
88
Walkup, G. K.; You, Z.; Ross, P. L.; Allen, E. K.; Daryaee, F.; Hale, M. R.; O'Donnell, J.;
Ehmann, D. E.; Schuck, V. J.; Buurman, E. T.; Choy, A. L.; Hajec, L.; Murphy-Benenato, K.;
Marone, V.; Patey, S. A.; Grosser, L. A.; Johnstone, M.; Walker, S. G.; Tonge, P. J.; Fisher, S.
L. Translating slow-binding inhibition kinetics into cellular and in vivo effects. Nature
Chemical Biology 2015, 11, 416–423.
89
Miller, D.; Lunn, G.; Jones, P.; Sabnis, Y.; Davies, N.; Driscoll, P. Investigation of the effect of
molecular properties on the binding kinetics of a ligand to its biological target.
MedChemComm 2012, 3, 449–452.
90
Schneider, E. V.; Böttcher, J.; Huber, R.; Maskos, K.; Neumann, L. Structure–kinetic
relationship study of CDK8/CycC specific compounds. Proceedings of the National Academy
of Sciences of the United States of America 2013, 110, 8081–8086.
91
Yang, Y.; Lightstone, F. C.; Wong, S. E. Approaches to efficiently estimate solvation and
explicit water energetics in ligand binding: the use of WaterMap. Expert Opinion on Drug
Discovery 2013, 8, 277–287.
92
Cappel, D.; Sherman, W.; Beuming, T. Calculating water thermodynamics in the binding site
156
of proteins - applications of WaterMap to drug discovery. Current Topics in Medicinal
Chemistry 2017, 17, 2586–2598.
93
Chang, C. E.; Chen, W.; Gilson, M. K. Ligand configurational entropy and protein
binding. Proceedings of the National Academy of Sciences of the United States of
America 2007, 104, 1534–1539.
94
Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational
approaches to estimate solubility and permeability in drug discovery and development settings.
Advanced Drug Delivery Reviews 1997, 23, 4−25.
95
DeGoey, D. A.; Chen, H. J.; Cox, P. B.; Wendt, M. D. Beyond the rule of 5: lessons learned
from AbbVie's drugs and compound collection. Journal of Medicinal Chemistry 2018, 61,
2636–2651.
96
Shultz M. D. Two decades under the influence of the rule of five and the changing properties
of approved oral drugs. Journal of Medicinal Chemistry 2019, 62, 1701–1714.
97
Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: a useful metric for lead selection.
Drug Discovery Today 2004, 9, 430–431.
98
Wang, Y.; Kun Huang, Gao, Y.; Yuan, D.; Ling, L.; Liu, J.; Wu, S.; Chen, R.; Li, H.; Xiong, Y.;
Liu, H.; Ma, J. Discovery of quinazoline derivatives as novel small-molecule inhibitors
targeting the programmed cell death-1/programmed cell death-ligand 1 (PD-1/PD-L1)
interaction. European Journal of Medicinal Chemistry 2022, 229, 113998.
99
OuYang, Y.; Gao, J.; Zhao, L.; Lu, J.; Zhong, H.; Tang, H.; Jin, S.; Yue, L.; Li, Y.; Guo, W.;
Xu, Q.; Lai, Y. Design, synthesis, and evaluation of o-(biphenyl-3-ylmethoxy)nitrophenyl
derivatives as PD-1/PD-L1 inhibitors with potent anticancer efficacy in vivo. Journal of
Medicinal Chemistry 2021, 64, 7646–7666.
100
Song, Z.; Liu, B.; Peng, X.; Gu, W.; Sun, Y.; Xing, L.; Xu, Y.; Geng, M.; Ai, J.; Zhang, A.
157
Design, synthesis, and pharmacological evaluation of biaryl-containing PD-1/PD-L1
interaction inhibitors bearing a unique difluoromethyleneoxy linkage. Journal of Medicinal
Chemistry 2021, 64, 16687–16702.
101
Cao, H.; Cheng, B.; Liu, T.; Chen, J. Synthesis and pharmacological evaluation of novel
resorcinol biphenyl ether analogs as small molecule inhibitors of PD-1/PD-L1 with benign
toxicity profiles for cancer treatment. Biochemical Pharmacology 2021, 188, 114522.
102
Muszak, D.; Surmiak, E.; Plewka, J.; Magiera-Mularz, K.; Kocik-Krol, J.; Musielak, B.; Sala,
D.; Kitel, R.; Stec, M.; Weglarczyk, K.; Siedlar, M.; Dömling, A.; Skalniak, L.; Holak, T. A.
terphenyl-based small-molecule inhibitors of programmed cell death-1/programmed deathligand 1 protein-protein interaction. Journal of Medicinal Chemistry 2021, 64, 11614–11636.
103
Qin, M.; Cao, Q.; Zheng, S.; Tian, Y.; Zhang, H.; Xie, J.; Xie, H.; Liu, Y.; Zhao, Y.; Gong, P.
Discovery of [1,2,4]triazolo[4,3-a]pyridines as potent inhibitors targeting the programmed cell
death-1/programmed cell death-ligand 1 interaction. Journal of Medicinal Chemistry 2019, 62,
4703–4715.
104
Guo, J.; Luo, L.; Wang, Z.; Hu, N.; Wang, W.; Xie, F.; Liang, E.; Yan, X.; Xiao, J.; Li, S. Design,
synthesis, and biological evaluation of linear aliphatic amine-linked triaryl derivatives as
potent small-molecule inhibitors of the programmed cell death-1/programmed cell deathligand 1 interaction with promising antitumor effects in vivo. Journal of Medicinal
Chemistry 2020, 63, 13825–13850.
105
Wang, T.; Cai, S.; Wang, M.; Zhang, W.; Zhang, K.; Chen, D.; Li, Z.; Jiang, S. Novel biphenyl
pyridines as potent small-molecule inhibitors targeting the programmed cell death1/programmed cell death-ligand 1 interaction. Journal of Medicinal Chemistry 2021, 64,
7390–7403.
106
Zhang, H.; Xia, Y.; Yu, C.; Du, H.; Liu, J.; Li, H.; Huang, S.; Zhu, Q.; Xu, Y.; Zou, Y. Discovery
158
of novel small-molecule inhibitors of PD-1/PD-L1 interaction via structural simplification
strategy. Molecules 2021, 26, 3347.
107
Cheng, B.; Ren, Y.; Niu, X.; Wang, W.; Wang, S.; Tu, Y.; Liu, S.; Wang, J.; Yang, D.; Liao, G.;
Chen, J. Discovery of novel resorcinol dibenzyl ethers targeting the programmed cell death1/programmed cell death-ligand 1 interaction as potential anticancer agents. Journal of
Medicinal Chemistry 2020, 63, 8338–8358.
108
Deng, J.; Cheng, Z.; Long, J.; Dömling, A.; Tortorella, M.; Wang, Y. Small molecule inhibitors
of programmed cell death ligand 1 (PD-L1): A patent review (2019-2021). Expert Opinion on
Therapeutic Patents 2022, 32, 575–589.
109
Koblish, H. K.; Wu, L.; Wang, L. S.; Liu, P. C. C.; Wynn, R.; Rios-Doria, J.; Spitz, S.; Liu, H.;
Volgina, A.; Zolotarjova, N.; Kapilashrami, K.; Behshad, E.; Covington, M.; Yang, Y. O.; Li,
J.; Diamond, S.; Soloviev, M.; O'Hayer, K.; Rubin, S.; Kanellopoulou, C.; Yang, G.; Rupar,
M.; DiMatteo, D.; Lin, L.; Stevens, C.; Zhang, Y.; Thekkat, P.; Geschwindt, R.; Marando, C.;
Yeleswaram, S.; Jackson, J.; Scherle, P.; Huber, R.; Yao, W.; Hollis, G. Characterization of
INCB086550: a potent and novel small-molecule PD-L1 inhibitor. Cancer Discovery 2022, 12,
1482–1499.
110
https://www.clinicaltrials.gov/ct2/show/NCT04049617
111
https://www.chemocentryx.com/pipeline/
112
Sasikumar, P. G.; Ramachandra, M. Small molecule agents targeting PD-1 checkpoint pathway
for cancer immunotherapy: mechanisms of action and other considerations for their advanced
development. Frontiers in Immunology 2022, 13, 752065.
113
Li, S. C.; Vilalta, M.; Ertl, L. S.; Wang, Y.; Zeng, Y.; Fan, P.; Lange, C.; McMurtrie, D.;
Yang, J.; Lui, R.; Ong, R.; Chhina, V.; Kumamoto, A.; Yau, S.; Dang, T.; Easterday, A.;
Liu, S.; Singh, R.; Charo, I.; Schall, T. J.; Zhang, P. Anti-tumor effect of orally available small
159
molecule PD-L1 inhibitors in a murine model of colon adenocarcinoma. Cancer Research
2020, 80(16_Supplement), 5693.
114
Graupe, M.; Medley, J.; Cho, A.; Guerrero, J.; Phillips, B.; Simonovich, S.; Watkins, W.; Yang,
K.; Appleby, T.; Villasenor, A.; Mukherjee, P.; Lad, L.; Wang, A.; Odegard, J.; Belzile, J. P.;
Morar, M.; Nazareno, J.; Stapleton, L. GS-4224: A potent, oral small molecule PD-L1 inhibitor.
ACS FALL 2022, 2022.
115
Park, J. J.; Thi, E. P.; Carpio, V. H.; Bi, Y.; Cole, A. G.; Dorsey, B. D.; Fan, K.; Harasym, T.;
Iott, C. L.; Kadhim, S.; Kim, J. H.; Lee, A. C. H.; Nguyen, D.; Paratala, B. S.; Qiu, R.; White,
A.; Lakshminarasimhan, D.; Leo, C.; Suto, R. K.; Rijnbrand, R.; Tang, S.; Sofia, M. J.; Moore,
C. B. Checkpoint inhibition through small molecule-induced internalization of programmed
death-ligand 1. Nature Communications 2021, 12, 1222.
116
Wang, T.; Cai, S.; Cheng, Y.; Zhang, W.; Wang, M.; Sun, H.; Guo, B.; Li, Z.; Xiao, Y.; Jiang,
S. Discovery of small-molecule inhibitors of the PD-1/PD-L1 axis that promote PD-L1
internalization and degradation. Journal of Medicinal Chemistry 2022, 65, 3879–3893.
117
Zhang, N.; Dou, Y.; Liu, L.; Zhang, X.; Liu, X.; Zeng, Q.; Liu, Y.; Yin, M.; Liu, X.; Deng, H.;
Song, D. SA-49, a novel aloperine derivative, induces MITF-dependent lysosomal degradation
of PD-L1. EBioMedicine 2019, 40, 151–162.
118
Cheng, B.; Ren, Y.; Cao, H.; Chen, J. Discovery of novel resorcinol diphenyl ether-based
PROTAC-like molecules as dual inhibitors and degraders of PD-L1. European Journal of
Medicinal Chemistry 2020, 199, 112377.
119
Ofori, S.; Awuah, S. G. Small-molecule poly(ADP-ribose) polymerase and PD-L1 inhibitor
conjugates as dual-action anticancer agents. ACS Omega 2019, 4, 12584–12597.
120
Zhu, H.; Bengsch, F.; Svoronos, N.; Rutkowski, M. R.; Bitler, B. G.; Allegrezza, M. J.;
Yokoyama, Y.; Kossenkov, A. V.; Bradner, J. E.; Conejo-Garcia, J. R.; Zhang, R. BET
160
bromodomain
inhibition
promotes
anti-tumor
immunity
by
suppressing
PD-L1
express ...
論文の公開元へ
